Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 85,971 matching trials from the live ClinicalTrials.gov search.
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Caregiving for Cancer
Interventions
Psychosocial Intervention for Parental Caregivers of AYA with Cancer
Behavioral
Lead sponsor
Zeba Ahmad, Ph.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Tobacco Use Cessation, Tobacco Use, Tobacco Smoking, Tobacco Chewing, Tobacco Dependence
Interventions
Clinic Level: AAC - SDOH, AAC - Tobacco, Non-Bundled, Bundled, Dose 1, Dose 3, Dose 6, Dose 9, Dose 12, RPN, PPN
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Neoplasm
Interventions
PTK787/ZK222584
Drug
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 4 more
Conditions
Anxiety Depression, HIV/AIDS
Interventions
Acupuncture, Chiropractic
Other
Lead sponsor
Yo San University of Traditional Chinese Medicine
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine

NCT00584805
Conditions
Eastern Equine Encephalitis
Interventions
Inactivated, Dried, TSI-GSD 104, EEE
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
1
States / cities
Fort Deterick, Maryland
Conditions
Ankle Sprain
Interventions
diclofenac sodium, Matching placebo patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Conditions
Brain Metastases, Brain Metastases, Adult, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Breast Cancer
Interventions
BEZ235, BKM 120, Letrozole, BKM120
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Conditions
Prostate Cancer, Prostatectomy
Interventions
Sunitinib Malate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Conditions
Malignant Glioma
Interventions
D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions
Atezolizumab, Tivozanib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Skin Laxity
Interventions
2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation, 2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation
Device
Lead sponsor
FA Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

Human Factor Validation of Pediatric Mobility Device

NCT03714256
Conditions
Disability Physical
Interventions
Device, patient mobility, powered
Device
Lead sponsor
Permobil, Inc.
Industry
Eligibility
6 Months to 36 Months
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Corvallis, Oregon • Nashville, Tennessee
Conditions
Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity, Cardiovascular Disease
Interventions
Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants, Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Farmington, Connecticut • Hartford, Connecticut • Storrs, Connecticut
Recruiting Not applicable Interventional Accepts healthy volunteers

The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)

NCT06524856
Conditions
Dyspnea, Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Lung Master (Pulmonary Exerciser)
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Retrospective Study, Glioma, Brain Neoplasms
Interventions
18F(FET)PET
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
Not listed
Enrollment
253 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

FACBC for Recurrent Prostate Cancer

NCT01808222
Conditions
Recurrent Prostate Cancer
Interventions
FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Healthy Volunteers, no Condition, Basic Science
Interventions
Transcranial Focused Ultrasound Stimulation, Electroencephalography, Magnetic Resonance Imaging
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Thrombocytopenia, Platelet Transfusion Refractoriness
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
3 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Child Health, Text Messaging
Interventions
Text message reminders, Interviews, Survey
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Stroke
Interventions
Virtual Reality (VR)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Birmingham, Alabama
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19

NCT06766279
Conditions
Anosmia
Interventions
Osteopathic Manipulative Treatment, Sham treatment
Procedure
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Cruces, New Mexico
Conditions
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
Other · Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio